UW researchers found potential new treatments for a rare pediatric brain cancer each year that has a median survival time of ...

Rondell Sheridan spent years making millions of kids laugh as the dad from That’s So Raven. In 2025, a GoFundMe organized on ...

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is ...

Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), ...

A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for ...

In this analysis from the phase 3 S1826 study, researchers aimed to show the durability of the efficacy of nivolumab plus doxorubicin, vinblastine, and dacarbazine in classic Hodgkin lymphoma.

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...